Omzo vs BreezeMeds: Compounded vs Branded GLP-1 Options

If you need a side-by-side look at Omzo vs BreezeMeds, the quick verdict is: Omzo emphasizes personalized compounded semaglutide and tirzepatide with clinician-guided plans starting at $179, while BreezeMeds highlights injectable and oral GLP-1 options with semaglutide starting at $199 and additional oral options shown from $399.

Explore Omzo clinician-guided plans

Key differences at a glance

This comparison focuses on the most distinctive differences supported by the sources: pricing and starting offers, medication form and compounding status, clinician involvement and prescriptions, shipping and delivery, and regulatory notes on compounded products. The Omzo vs BreezeMeds question is addressed across these areas below.

Pricing and visible starting offers

Omzo lists personalized compounded semaglutide starting at $179 and tirzepatide starting at $279. BreezeMeds lists semaglutide injection from $199 per month, tirzepatide injection from $299, and oral options displayed from $399; a separate $169 figure appears without clear product association. Both providers suggest confirming total cost, eligibility, and state availability before enrolling.

Medication types and compounding status

Omzo highlights a primary compounded medication program offering compounded semaglutide and tirzepatide prepared and shipped by a state-licensed sterile compounding pharmacy, and notes that these compounded drugs are not FDA-approved. Omzo also states providers may write prescriptions for branded FDA-approved medications, but Omzo does not sell, dispense, or ship branded drugs.

BreezeMeds presents injectable and oral GLP-1 options, including semaglutide and tirzepatide, and states that when compounded medications are offered they are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. BreezeMeds displays oral semaglutide and oral tirzepatide pricing starting at $399, and emphasizes discreet delivery.

Clinician oversight and prescription process

Both platforms present clinician review as part of access to medication. Omzo connects users with licensed U.S. providers who determine eligibility and prescribe based on professional judgment; providers make the final determination as to whether to prescribe any medication. Omzo explicitly says clinical services are provided by third party networks of U.S.-licensed clinicians and that using the website does not create a doctor patient relationship.

BreezeMeds also indicates treatment is available only when a licensed clinician determines it is medically appropriate and refers to an online intake and personalized treatment plan. Both sources advise confirming eligibility and state availability before enrollment.

Check Omzo clinician-reviewed options

Shipping, delivery, and service notes

Omzo promotes fast, discreet delivery and notes FSA and HSA eligibility for its programs. Omzo also states medication costs are included in fees collected by Omzo and that Omzo pays the pharmacies, while noting rates may vary based on pharmacy capacity, state regulations, and order details.

BreezeMeds emphasizes discreet home delivery and ongoing support. BreezeMeds lists starting prices and asks users to confirm what states it services and details such as insurance acceptance and fees.

Regulatory and approval information

Both sources include regulatory qualifiers. Omzo explicitly states compounded medications offered are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. BreezeMeds notes that medication-specific approval status must be confirmed and that branded and compounded products are not interchangeable. Both recommend verifying medication and regulatory status with clinicians.

How to choose between Omzo and BreezeMeds

Omzo vs BreezeMeds boils down to priorities you can confirm from each source. Omzo centers on a compounded medication program with clinician-guided plans and lower listed starting prices for compounded semaglutide. BreezeMeds highlights both injectable and oral options at higher listed starting prices and stresses discreet delivery and an online intake for clinician review.

Start Omzo eligibility check

Choose Omzo if you want access to a clinician-guided compounded program with semaglutide starting at $179 and you understand compounded products are not FDA-approved and that providers determine prescriptions. Choose BreezeMeds if you prefer a platform that displays injectable and oral GLP-1 options with semaglutide shown from $199, or if you want to review oral formulations and discreet home delivery options. For both, confirm eligibility, medication details, total cost, renewal terms, and state availability before enrolling.